| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEP.22771 |
| P698 | PubMed publication ID | 19185005 |
| P50 | author | Frank G. Schaap | Q42394202 |
| P2093 | author name string | Peter L M Jansen | |
| Dirk J Gouma | |||
| Niels A van der Gaag | |||
| P2860 | cites work | Mini-review: endocrine actions of fibroblast growth factor 19. | Q37052076 |
| Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis | Q40183754 | ||
| The nuclear bile acid receptor FXR is activated by PGC-1alpha in a ligand-dependent manner | Q41850783 | ||
| Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia | Q46713424 | ||
| Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. | Q53331692 | ||
| Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. | Q54017726 | ||
| Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. | Q54771768 | ||
| Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis | Q81721898 | ||
| Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain | Q22001492 | ||
| Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors | Q24290397 | ||
| Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis | Q24305561 | ||
| Liver-specific activities of FGF19 require Klotho beta | Q24319088 | ||
| Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology | Q25255128 | ||
| The continuing importance of bile acids in liver and intestinal disease | Q28140260 | ||
| The enzymes, regulation, and genetics of bile acid synthesis | Q28204726 | ||
| Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine | Q28242281 | ||
| Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents | Q28292663 | ||
| LXRS and FXR: the yin and yang of cholesterol and fat metabolism | Q28295718 | ||
| Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data | Q29616220 | ||
| Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis | Q29619610 | ||
| Preoperative biliary drainage for periampullary tumors causing obstructive jaundice; DRainage vs. (direct) OPeration (DROP-trial) | Q33277947 | ||
| Nuclear receptors. I. Nuclear receptors and bile acid homeostasis | Q34642552 | ||
| Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis | Q36066753 | ||
| Enterohepatic transport of bile salts and genetics of cholestasis | Q36173464 | ||
| Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration | Q36732805 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| extrahepatic cholestasis | Q18554560 | ||
| P304 | page(s) | 1228-1235 | |
| P577 | publication date | 2009-04-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis | |
| P478 | volume | 49 |
| Q57125740 | Q57125740 |
| Q52577718 | A Novel Fibroblast Growth Factor 15 Dependent- and Bile Acid Independent-Promotion of Liver Regeneration in Mice. |
| Q53233233 | A nontumorigenic variant of FGF19 treats cholestatic liver diseases. |
| Q33993142 | A putative role of micro RNA in regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes |
| Q41679642 | ABC gene-ranking for prediction of drug-induced cholestasis in rats |
| Q42497435 | Activation of p38 Mitogen-Activated Protein Kinase by Clotrimazole Induces Multidrug Resistance-Associated Protein 3 Activation through a Novel Transcriptional Element. |
| Q45873421 | Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. |
| Q54274187 | Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients. |
| Q26800206 | Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer |
| Q35257218 | Bile Acid signaling in liver metabolism and diseases |
| Q27002873 | Bile acid metabolism and signaling |
| Q38132058 | Bile acid receptors as targets for drug development. |
| Q57128781 | Bile acid receptors link nutrient sensing to metabolic regulation |
| Q28244875 | Bile acid signaling in metabolic disease and drug therapy |
| Q26863752 | Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases |
| Q24652624 | Bile acid transporters |
| Q38033967 | Bile acid transporters and regulatory nuclear receptors in the liver and beyond |
| Q94475532 | Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease |
| Q24658139 | Bile acids: regulation of synthesis |
| Q34108895 | Biliary physiology and disease: reflections of a physician-scientist |
| Q57148414 | Calorie restriction and Roux-en-Y gastric bypass have opposing effects on circulating FGF21 in morbidly obese subjects |
| Q36390520 | Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis |
| Q50067222 | Changes of organic anion transporter MRP4 and related nuclear receptors in human obstructive cholestasis |
| Q57145981 | Characterization and treatment of persistent hepatocellular secretory failure |
| Q36389501 | Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis |
| Q57118362 | Circulating Fibroblast Growth Factor 19 in Portal and Systemic Blood |
| Q28655881 | Cystic fibrosis related liver disease--another black box in hepatology |
| Q39741716 | Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlr -/- mice versus hamsters |
| Q37837616 | Ductal plates in hepatic ductular reactions. Hypothesis and implications. III. Implications for liver pathology |
| Q97074477 | Dysregulation of Circulating FGF19 and Bile Acids in Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome |
| Q52588722 | Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. |
| Q35815498 | Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-s |
| Q48246813 | Embryonic cholecystitis and defective gallbladder contraction in the Sox17-haploinsufficient mouse model of biliary atresia. |
| Q38023300 | Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. |
| Q26781556 | Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy |
| Q24629260 | Endocrine fibroblast growth factors 15/19 and 21: from feast to famine |
| Q37337378 | Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice |
| Q35027404 | Enterohepatic bacterial infections dysregulate the FGF15-FGFR4 endocrine axis |
| Q54227364 | Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways. |
| Q35979451 | Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease |
| Q37163001 | FGF15/19 protein levels in the portal blood do not reflect changes in the ileal FGF15/19 or hepatic CYP7A1 mRNA levels |
| Q51737577 | FXR Activation by Obeticholic Acid or Non-Steroidal Agonists Induces a Human-Like Lipoprotein Cholesterol Change in Mice with Humanized Chimeric Liver. |
| Q58590159 | FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis |
| Q47140461 | Fibroblast Growth Factor 19 Activates the Unfolded Protein Response and Mitogen-Activated Protein Kinase Phosphorylation in H-69 Cholangiocyte Cells |
| Q42263341 | Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea. |
| Q91663832 | Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor |
| Q35998475 | Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers |
| Q64973345 | Fibroblast growth factors 19 and 21 in acute liver damage. |
| Q92503336 | Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application |
| Q35020888 | Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease |
| Q50163355 | Functions of the Gallbladder |
| Q92747286 | Gallbladder Dyskinesia Is Associated With an Impaired Postprandial Fibroblast Growth Factor 19 Response in Critically Ill Patients |
| Q38839321 | Gastroenterological endpoints in drug trials for cystic fibrosis |
| Q34024552 | Getting the mOST from OST: Role of organic solute transporter, OSTalpha-OSTbeta, in bile acid and steroid metabolism |
| Q35583781 | Hepatic expression of detoxification enzymes is decreased in human obstructive cholestasis due to gallstone biliary obstruction |
| Q26829300 | Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk |
| Q37781747 | Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease |
| Q34627935 | Impact of global Fxr deficiency on experimental acute pancreatitis and genetic variation in the FXR locus in human acute pancreatitis |
| Q37529052 | Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis |
| Q44664597 | In vivo degradation of cholesterol to bile acids is reduced in patients receiving parenteral nutrition |
| Q48143345 | Integrative "-Omics" Analysis in Primary Human Hepatocytes Unravels Persistent Mechanisms of Cyclosporine A-Induced Cholestasis. |
| Q34534282 | Interleukin-13 Activates Distinct Cellular Pathways Leading to Ductular Reaction, Steatosis, and Fibrosis |
| Q44427743 | Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. |
| Q97643831 | Metabolic Messengers: fibroblast growth factor 15/19 |
| Q47723879 | Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience |
| Q92568302 | Modulation of bile acid profile by gut microbiota in chronic hepatitis B |
| Q36108941 | Negative feedback regulation of bile acid metabolism: impact on liver metabolism and diseases |
| Q39044702 | New therapeutic concepts in bile acid transport and signaling for management of cholestasis. |
| Q47223909 | New therapies target the toxic consequences of cholestatic liver disease |
| Q33716459 | Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis |
| Q93341205 | Novel in Vitro Method Reveals Drugs That Inhibit Organic Solute Transporter Alpha/Beta (OSTα/β) |
| Q48532540 | Nuclear receptor regulation of bile acid and nutrient metabolism: 51st Annual Max Miller Lecture in Diabetes Research presented by David Mangelsdorf, PhD. |
| Q36786270 | Nuclear receptors as drug targets in cholestatic liver diseases |
| Q38074995 | Nuclear receptors in bile acid metabolism |
| Q89837444 | Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism |
| Q50116444 | Organic Solute Transporter OSTα/ß is Over-Expressed in Nonalcoholic Steatohepatitis and Modulated by Drugs Associated with Liver Injury. |
| Q37737636 | Organic solute transporter, OSTalpha-OSTbeta: its role in bile acid transport and cholestasis |
| Q34992341 | Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis. |
| Q86779136 | Pandora's box opens for cholestatic liver disease |
| Q92535838 | Paracrine Fibroblast Growth Factor 1 Functions as Potent Therapeutic Agent for Intrahepatic Cholestasis by Downregulating Synthesis of Bile Acid |
| Q92763064 | Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis |
| Q34493836 | Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis. |
| Q36987335 | Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules |
| Q36843966 | Pleiotropic roles of bile acids in metabolism |
| Q90393605 | Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice |
| Q33961753 | Profiling circulating and urinary bile acids in patients with biliary obstruction before and after biliary stenting |
| Q37584099 | Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge |
| Q24626582 | Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice |
| Q46933007 | Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis |
| Q37121662 | Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. |
| Q35690177 | Regulation of hepatic ABCC transporters by xenobiotics and in disease states |
| Q33993174 | Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms |
| Q35564302 | Scoparone potentiates transactivation of the bile salt export pump gene and this effect is enhanced by cytochrome P450 metabolism but abolished by a PKC inhibitor |
| Q54316297 | Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. |
| Q57147773 | Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype |
| Q57113921 | Solute Carrier Organic Anion Transporter Family Member 3A1 is a Bile Acid Efflux Transporter in Cholestasis |
| Q24306135 | Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho |
| Q59328880 | Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis |
| Q38176101 | Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations |
| Q92051727 | The Effect of Fibroblast Growth Factor 15 Signaling in Non-Steatotic and Steatotic Liver Transplantation from Cardiocirculatory Death |
| Q93180147 | The FGF metabolic axis |
| Q39040911 | The ascending pathophysiology of cholestatic liver disease. |
| Q34094150 | The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. |
| Q34219880 | The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. |
| Q53635376 | The molecular mechanism underlying the induction of hepatic MRP3 expression and function by omeprazole. |
| Q38070531 | The molecular pathogenesis of cholestasis in sepsis |
| Q35532506 | The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes |
| Q37556251 | The portal-drained viscera release fibroblast growth factor 19 in humans |
| Q37985453 | The use of stable and radioactive sterol tracers as a tool to investigate cholesterol degradation to bile acids in humans in vivo. |
| Q38633258 | Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. |
| Q34418685 | Upregulation of hepatic bile acid synthesis via fibroblast growth factor 19 is defective in gallstone disease but functional in overweight individuals |
| Q38639954 | Validation of gene expression profiles from cholestatic hepatotoxicants in vitro against human in vivo cholestasis. |
Search more.